drugset / Trial / NCT06802666

Short-course Radiotherapy Followed by AK112 and CAPOX as Neoadjuvant Therapy for Locally Advanced Rectal Cancer

NCT06802666

NaSingle-groupOpen-labelTreatment

Summary

This study aims to evaluate the efficacy and safety of short-course radiotherapy followed by AK112 in combination with CAPOX as neoadjuvant therapy in patients with locally advanced rectal cancer

Timeline

Start
2024-10-16
Primary completion
2026-09-01
Completion
2027-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Capecitabine Small molecule 1000 mg/m2
Subject Ivonescimab Monoclonal antibody 20 mg/kg Intravenous
Subject Oxaliplatin Small molecule 130 mg/m2 Intravenous

Indications

No indication recorded.